Paper39748838
Alzheimer's disease drug development in an evolving therapeutic landscape.
Weninger S and 8 others. Alzheimers Dement (N Y), 2024. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Alzheimer's disease drug development in an evolving therapeutic landscape. Papers, record 39748838. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39748838
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References25
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30410033 | Multiple sclerosis. | Nat Rev Dis Primers | 2018 | https://conductscience.org/library/papers/30410033 | PubMed |
| 2 | 34289882 | The informed road map to prevention of Alzheimer Disease: A call to arms. | Mol Neurodegener | 2021 | https://conductscience.org/library/papers/34289882 | PubMed |
| 3 | 33720637 | Donanemab in Early Alzheimer's Disease. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33720637 | PubMed |
| 4 | 24928124 | Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. | Neurology | 2014 | https://conductscience.org/library/papers/24928124 | PubMed |
| 5 | 36449413 | Lecanemab in Early Alzheimer's Disease. | N Engl J Med | 2023 | https://conductscience.org/library/papers/36449413 | PubMed |
| 6 | 33865446 | A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. | Alzheimers Res Ther | 2021 | https://conductscience.org/library/papers/33865446 | PubMed |
| 7 | 34331706 | "Real world" eligibility for aducanumab. | J Am Geriatr Soc | 2021 | https://conductscience.org/library/papers/34331706 | PubMed |
| 8 | 35542991 | Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease. | J Prev Alzheimers Dis | 2022 | https://conductscience.org/library/papers/35542991 | PubMed |
| 9 | 28767357 | Evidence for Health Decision Making - Beyond Randomized, Controlled Trials. | N Engl J Med | 2017 | https://conductscience.org/library/papers/28767357 | PubMed |
| 10 | 33043108 | Advancing combination therapy for Alzheimer's disease. | Alzheimers Dement (N Y) | 2020 | https://conductscience.org/library/papers/33043108 | PubMed |
| 11 | 32161412 | A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. | Nat Med | 2020 | https://conductscience.org/library/papers/32161412 | PubMed |
| 12 | 34155411 | A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. | Nat Med | 2021 | https://conductscience.org/library/papers/34155411 | PubMed |
| 13 | 37251912 | Alzheimer's disease drug development pipeline: 2023. | Alzheimers Dement (N Y) | 2023 | https://conductscience.org/library/papers/37251912 | PubMed |
| 14 | 36655336 | Anti-amyloid antibody therapies in Alzheimer's disease. | Brain | 2023 | https://conductscience.org/library/papers/36655336 | PubMed |
| 15 | 39350367 | Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force. | J Prev Alzheimers Dis | 2024 | https://conductscience.org/library/papers/39350367 | PubMed |
| 16 | 36730056 | Tilavonemab in early Alzheimer's disease: results from a phase 2, randomized, double-blind study. | Brain | 2023 | https://conductscience.org/library/papers/36730056 | PubMed |
| 17 | 37586881 | Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging. | Neurology | 2023 | https://conductscience.org/library/papers/37586881 | PubMed |
| 18 | 21211070 | Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. | Alzheimers Res Ther | 2011 | https://conductscience.org/library/papers/21211070 | PubMed |
| 19 | 37097366 | Randomized Trials vs Real-world Evidence: How Can Both Inform Decision-making? | JAMA | 2023 | https://conductscience.org/library/papers/37097366 | PubMed |
| 20 | 39748838 | Alzheimer's disease drug development in an evolving therapeutic landscape. | Alzheimers Dement (N Y) | 2024 | https://conductscience.org/library/papers/39748838 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42382756 | Calibrating microglia states in Alzheimer's disease: decoding immune-metabolic networks and nano-targeted multicomponent therapies. | Front Immunol | 2026 | https://conductscience.org/library/papers/42382756 | PubMed |
| 42118396 | From Molecular Networks to Medicines: Targeting Complexity in Alzheimer's Disease (AD) Therapy. | Mol Neurobiol | 2026 | https://conductscience.org/library/papers/42118396 | PubMed |
| 40529145 | Integrating genetic and immune profiles for personalized immunotherapy in Alzheimer's disease. | Front Med (Lausanne) | 2025 | https://conductscience.org/library/papers/40529145 | PubMed |
| 39748838 | Alzheimer's disease drug development in an evolving therapeutic landscape. | Alzheimers Dement (N Y) | 2024 | https://conductscience.org/library/papers/39748838 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39748838
GET https://conductscience.org/api/papers/v1/39748838/references?page=2